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A novel biomarker of MMp‑cleaved 
prolargin is elevated in patients 
with psoriatic arthritis
Dovile Sinkeviciute1,2*, Solveig Skovlund Groen1,3, Shu Sun1, Tina Manon‑Jensen1, 
Anders Aspberg2, Patrik Önnerfjord2, Anne‑Christine Bay‑Jensen1, Salome Kristensen4 & 
Signe Holm nielsen1,5
Psoriatic arthritis (PsA) is a chronic musculoskeletal inflammatory disease found in up to 30% of 
psoriasis patients. prolargin—an extracellular matrix (ecM) protein present in cartilage and tendon—
has been previously shown elevated in serum of patients with psoriasis. ECM protein fragments can 
reflect tissue turnover and pathological changes; thus, this study aimed to develop, validate and 
characterize a novel biomarker pRoM targeting a matrix metalloproteinase (MMp)‑cleaved prolargin 
neo‑epitope, and to evaluate it as a biomarker for PsA. A competitive ELISA was developed with a 
monoclonal mouse antibody; dilution‑ and spiking‑recovery, inter‑ and intra‑variation, and accuracy 
were evaluated. Serum levels were evaluated in 55 healthy individuals and 111 patients diagnosed 
with PsA by the CASPAR criteria. Results indicated that the PROM assay was specific for the neo‑
epitope. Inter‑ and intra‑ assay variations were 11% and 4%, respectively. PROM was elevated 
(p = 0.0003) in patients with PsA (median: 0.24, IQR: 0.19–0.31) compared to healthy controls (0.18; 
0.14–0.23) at baseline. AUROC for separation of healthy controls from PsA patients was 0.674 (95% CI 
0.597–0.744, P < 0.001). In conclusion, MMP‑cleaved prolargin can be quantified in serum by the PROM 
assay and has the potential to separate patients with PsA from healthy controls.
Psoriatic arthritis (PsA) is an inflammatory chronic joint disease that is found in up to 30% of psoriasis patients 
and can precede the skin manifestations of the  disease1,2. Risk factors for developing PsA are psoriasis severity, 
family history of the disease, psoriatic nail changes and polymorphisms in human leukocyte antigen (HLA) 
and major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA)  loci3. Men and 
women are equally  affected4. PsA typically affects the large joints, especially joints of the lower extremities, and 
distal joints of the fingers and toes, however it can also affect the spinal and sacroiliac joints of the  pelvis5. The 
number of involved joints varies among patients—several or only 1–2 joint can be affected, which leads to diverse 
clinical features, resulting in difficulties when diagnosing  patients4. Potential complications of PsA include eye 
problems, such as conjunctivitis or uveitis, cardiovascular disease, and arthritis mutilans—a severe, painful and 
disabling form of joint disease, where small bones of the hands are destroyed, leading to permanent deformity 
and  disability4,6.
The most common symptoms of PsA are joint and tendon pain, swollen fingers and toes, and lower back 
 pain4. No specific diagnostic test is available for psoriatic  arthritis4. Instead, the diagnosis is based on a combi-
nation of clinical criteria, blood tests, including erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP) to check for inflammation and x-rays or MRI scans for joint  damage3,5. There is no cure for the PsA at 
the moment, and the treatment focuses on symptom relief and prevention of joint  involvement7. Non-steroid 
anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs) and 
biological therapies are currently used to relieve pain, protect the joints, and maintain  mobility7. PsA gets pro-
gressively worse without intervention, but if diagnosed and treated early the disease progression can be slowed 
down and structural joint damage delayed or  prevented8. Considering that many patients with psoriasis have 
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undiagnosed PsA, and nearly 50% of patients with PsA will develop erosions in the first 2 years of the disease, 
predicting arthritis prior to its onset is vital for avoiding the  damage9–12.
Biomarkers are measurable biological indicators of disease activity that may be used to predict future disease, 
measure current disease activity, or quantify therapeutic efficacy. Therefore, biomarkers have been identified as 
a relevant research gap in  PsA13. In rheumatic diseases, the biomarkers are usually either genetic, serological, 
cellular, synovial or imaging  type14,15. Serological biomarkers obtained from peripheral blood are of particular 
interest since they can be easily accessible at the clinic. So far, some studies suggest serum interleukin (IL)-2, 
IL-10, MMP3 and vascular endothelial growth factor (VEGF) may be used to discriminate patients with PsA 
from patients with  psoriasis14. Collagen fragments, such as a released N-terminal pro-peptide of type II collagen 
(PRO-C2) have been shown to be increased in patients with PsA compared to healthy controls, thus potentially 
allowing for screening of the  disease16.
Prolargin, also known as PRELP (proline/arginine-rich end leucine-rich repeat protein) is a 58 kDa proteo-
glycan and a member of the small leucine-rich proteoglycan (SLRP)  family17. It is found in variety of extracel-
lular matrices, including cartilage matrix and basement  membranes18,19. It is also found in tissues such as in the 
sclera, kidney, tendon, skin, liver, lung, and  heart18,20. Prolargin has been shown to inhibit all three pathways 
of complement system and has been suggested to have a role in joint  disease21. In PsA patients, serum comple-
ment component 3 (C3) levels were reported higher than in control  group22. Since prolargin has previously been 
shown to inhibit the alternative pathway C3  convertase21, and its expression to be 1.35-fold higher in psoriasis 
group compared to controls in miR-31 microarray  assay23, it is likely relevant to PsA as well. Indeed, prolargin 
was recently suggested as a new protein candidate indicative of response to anti-tumor necrosis factor (TNF)-α 
in PsA, thus warranting further investigation of this protein in this  disease24.
In mass spectrometry analysis of matrix metalloproteinase (MMP)-degraded articular cartilage, prolargin 
was among the top 16 proteins from which the most abundantly released peptides originated  from25. MMPs 
are activated upon inflammation, which is the first step in PsA tissue injury process. Cartilage degradation in 
PsA has been linked to upregulation of pro-inflammatory cytokines TNF and IL-17—which, in turn, can lead 
to an increased production of  MMPs26–28. Indeed, MMP levels have been reported elevated in synovial fluid and 
serum of patients with  PsA29,30.
Thus, the aim of this study was to develop, validate and characterize a novel biomarker PROM targeting a 
MMP-generated neo-epitope specific fragment of prolargin, and thereafter evaluate its abilities as a biomarker for 
PsA. The neo-epitope biomarker technology is based on targeting the amino acid sequence at the new terminal 
of generated fragments.
Results
production and characterization of monoclonal antibodies. Antibody-producing clones were gen-
erated after fusion between mouse spleen cells and myeloma cells and the monoclonal antibody with the best 
native reactivity, peptide affinity, and stability for the assay was identified. Based on reactivity, we selected anti-
body clone NBH228-1F7-1D9-1D6-2D12. Antibody isotype was determined to be IgG1, kappa.
technical evaluation. During assay development we optimized the following parameters: buffers (pH and 
salt content), incubation temperature and time, coater and antibody ratio, testing of labeled and unlabeled anti-
body, stability and specificity of the mAb. We have selected the coater:mAb ratio based on B/B0 checkerboard 
assay results (Supplementary Fig.  S1) together with considering the total signal strength and serum sample 
screening results (criteria: healthy human serum samples should be on the measurement range). PBS-based 
buffer was selected due to a better pH long-term stability.
The technical validation was performed to evaluate the newly developed PROM assay. A summary of all 
the technical tests, can be found in Table 1. The assay measurement range lower limit (LLMR) and upper limit 
(ULMR) were determined to be 0.08 ng/ml and 2.04 ng/ml, respectively. The mean intra- and inter-assay varia-
tion based on 10 independent runs yielded a 4.1% and 10.6% recovery, respectively. Linearity of human serum 
was assessed from undiluted to an eightfold dilution. The analyte stability was acceptable for both 2–5 times 
freeze/thaw cycles and prolonged storage of human serum samples. Spiking of standard peptide in human serum 
resulted in a mean recovery of 63%, while serum in serum spiking resulted in a mean recovery of 93%. Neither 
low nor high levels of biotin, hemoglobin and lipids interfered with the levels of PROM in human serum.
The PROM assay specificity was tested towards synthetic peptides, to confirm the specificity of the cleavage 
fragment. No reactivity was found towards the elongated peptide, truncated peptide, nonsense peptide and 
nonsense coater (Fig. 1). In vitro cleavages experiments showed the assay PROM was generated predominantly 
by collagenases MMP-1 and MMP-13, and to a lesser extent by gelatinases MMP-2 and MMP-9 (Fig. 2).
Biological evaluation. PROM was measured in a biological validation cohort (Table 2), which consisted 
of healthy controls and patients with PsA at baseline. All patients and healthy controls were Caucasian. PROM 
levels were lower (p = 0.0003) in healthy individuals (median: 0.18; IQR: 0.14–0.23) compared to patients with 
PsA (median: 0.24, IQR: 0.19–0.31) (Fig. 3). After 24 weeks, the level of prolargin showed a borderline signifi-
cant decrease in the placebo group (p = 0.049), but no difference was observed in the n-3 polyunsaturated fatty 
acid (PUFA) treated group (Fig. 4). There was no significant difference between placebo and n-3 PUFA groups 
at baseline, nor at 24 weeks (Fig. 4). PROM levels also did not correlate with disease scores, sex, age, BMI or 
disease duration (Tables 3 and 4). The diagnostic power (AUROC) of PROM for separating a patient with PsA 
from healthy controls was 0.674 (95% CI 0.597–0.744, P = 0.001, Fig. 5).     
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Discussion
PsA is a progressive and disabling disease that remains  underdiagnosed6. Although Classification Criteria for 
Psoriatic Arthritis (CASPAR criteria)31 are used for providing guidance to the clinicians and for enrolling patients 
in clinical trials, we need biomarkers to better account for the diverse clinical presentation of PsA and to facilitate 
personalized medicine. Furthermore, the ability to detect patients with poor prognosis would help to choose 
which patients need a more aggressive treatment, and the ability to identify which medications would work best 
for an individual patient with PsA. This would address the fact that many patients must cycle through a number 
of medications before finding the one that works for  them8,32.
In this study we developed, validated and characterized a novel competitive ELISA detecting a MMP-gen-
erated prolargin fragment (PROM) using a monoclonal antibody. The main findings in this study were: (1) The 
novel assay was technically robust and specific to the target sequence, (2) the fragment was present in serum and 
plasma, (3) PROM was upregulated in patients with PsA compared to healthy controls, and (4) PROM did not 
show a difference in patients treated with PUFA treatment. We investigated the PUFA treatment, as marine n-3 
PUFAs have previously reduced inflammation, joint pain, and NSAID use in patients with rheumatoid arthritis 
(RA), and n-3 PUFA supplementation in patients with PsA led to a reduced use of NSAIDs and  paracetamol33 
as well as an improved heart rate and heart rate  variability34. However, there was no correlation to the disease 
scores, which we also do not see with PROM. Although it was not discriminatory in a diagnostic way, PROM 
might be useful combined with another biomarker or feature.
Table 1.  PROM ELISA technical validation data. a Mean (range) recovery percentages are reported.
Technical validation PROM
IC50 0.43 ng/mL
Detection range 0.08–2.04 ng/ml
Intra-assay  variationa 4.1 (1.18–6.86)
Inter-assay  variationa 10.6 (4.85–17.81)
Dilution (1:2) recovery in  seruma 100 (83–94)
Dilution (1:2) recovery in heparin  plasmaa 101 (88–122)
Interference biotin, low/high  ≤ 107%/ ≤ 102%
Interference lipemia, low/high  ≤ 103%/ ≤ 102%
Interference hemoglobin, low/high  ≤ 112%/ ≤ 107%
Freeze–thaw analyte stability (2 cycles)a 105 (102.2–108.6)
Analyte stability (stress test)
At 4 °C, the mean percent (SD) recovery was: 100 (5.8), 107 (14.1), 108 (20.0), 109 (3.8) after 
2, 4, 24, and 48 h, respectively
At 20 °C: 96 (10.9), 99 (17.0), 115 (11.0), 113 (14.4) after 2, 4, 24 and 48 h, respectively
Antibody stability (stress test)
Mean recovery (SD) after 7 days incubation:
At 4 °C: 114% (15.6)
At 20 °C: 110% (25.8)
Spike-in recovery (serum in serum)a 93 (80–115)
Figure 1.  Specificity of the PROM assay. The assay is specific to its selection peptide (HDFSSDLENV) and 
does not recognize truncated (DFSSDLENV), elongated (FHDFSSDLENV), or recombinant human prolargin 
protein (Gln21-Ile382), nor non-sense peptides (KSVDQASSRK). A twofold dilution of the peptides were 
added starting from 8 ng/ml. The background signal was tested using a non-sense coating peptide (Biotin-
KSVDQASSRK). The data is presented as relative light units (RLU) function of peptide concentration.
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The PROM ELISA was characterized as being a technically robust assay—it recognized only the selection pep-
tide in specificity assessment, and showed dilution recovery, stability and interference tests within the accepted 
range ± 20%. Additionally, the inter- and intra-assay variation was acceptable with values of 4.1% and 10.6%, 
respectively. The analyte and antibody were stable at 20 °C for up to 48 h and 7 days at 37 °C, respectively.
The work reported here has limitations—the healthy patients, despite being matched on age, race and sex, 
did not come from the same source as the PsA patients. Furthermore, the patients included in the PsA cohort 
had low disease activity /remission with approximately 75% of the participants in treatment with DMARDs. 
Olive oil was used as control, and while olive oil has often been used for this purpose in studies investigating 
the effects of n-3 PUFA, it may itself have anti-inflammatory actions. Additionally, we did not test if the bio-
marker is PsA-exclusive, nor did we look into cell signaling. In RA, cartilage tissue is destroyed and prolargin 
fragments are released into synovial fluid, where it is hypothesized that they interact with complement system 
components and downregulate complement activation, which has been shown to play a role in both initiating the 
inflammatory state and in maintaining the inflammation during chronic  disease35. Therefore, in future studies 
it would be interesting to investigate whether the neoepitope affects the complement system. Additionally, now, 
most biomarkers are not PsA specific, but rather indicate synovial inflammation and/or cartilage turnover in 
inflammatory joint disease. For example, active serum MMP3 levels decreased in both ankylosing spondylitis 
(AS) and RA after anti-TNFα  treatment36. Therefore, in the future studies PROM should be measured in other 
inflammatory joint diseases to ascertain whether it is PsA-specific, and whether it can distinguish patients with 
psoriasis that do not have PsA. The assay should also be measured in studies for treatment efficacy (e.g. IL-17/
IL-23 inhibitor studies) for further PROM validation in PsA.
In summary, MMP-cleaved prolargin can be quantified in serum by the PROM assay and has the potential 
to separate patients with PsA from healthy controls. To our knowledge this is the first study to develop a specific 
neo-epitope ELISA biomarker of prolargin and measure it in patients diagnosed with PsA.
Materials and methods
Reagents. Synthetic peptides were purchased from Genscript (Piscataway, NJ, US) and chemicals were pur-
chased from Sigma-Aldrich (St.Louis, MO, US) or Merck (Whitehouse Station, NJ, US).
production of monoclonal antibodies. Antibodies were raised against the 10 amino acid sequence 340′.
HDFSSDLENV’349 from prolargin cleaved in the C-terminus, which was discovered by mass spectrometry 
analysis of MMP-cleaved human articular cartilage samples and verified by BLAST to be unique for prolargin 
using NPS@: Network Protein Sequence Analysis with the UniprotKB/Swiss-prot  database25,37. Five mice were 
immunized by subcutaneous injection of 200 µL emulsified antigen and 50 µg immunogenic peptide (HDFSS-
DLENV-GGC-KLH) in 6–7 weeks old Balb/C female mice using Stimune Immunogenic Adjuvant (SPECOL) 
(Invitrogen, Carlsbad, CA, US). This was repeated every 2nd week until stable serum antibody titer levels were 
reached. The mouse with the highest serum titer was selected for fusion and rested for a month. Then, the mouse 
was boosted intravenously with 50 µg immunogenic peptide in 100 µL 0.9% NaCl solution three days before 
Figure 2.  PROM release from MMP-cleaved human articular cartilage. PROM fragment is released from 
MMP-1, MMP-2, MMP-9 and MMP-13-cleaved human articular cartilage (hOA cart.) obtained from end-stage 
OA patients undergoing total joint replacement surgery. Data shown is from one (n = 1) representative cartilage 
sample. Error bars represent standard deviation for two biopsies from the same cartilage sample.
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isolation of the spleen for cell fusion. The mouse spleen cells were fused with SP2/0 myeloma cells as described 
by Gefter et al. (1977), to produce hybridoma  cells38. After this, the clones were plated into 96-well microtiter 
plates for further growth and the limiting dilution method was applied to promote monoclonal growth. The 
positive clones were picked out for preliminary characterization including checkerboard and peptide inhibition. 
Two clones showed peptide inhibition and were chosen for further growth. A competitive ELISA was performed 
on streptavidin-coated plates to screen supernatant reactivity. HDFSSDLENVK-Biotin was used as screening 
peptide, while the selection peptide HDFSSDLENV was used to test specificity of the clones. Antibody isotype 
determination was performed using commercial Rapid ELISA Mouse mAb Isotyping Kit (Invitrogen, Carlsbad, 
CA, US) following the manufacturer’s instructions. Clone 1F7 was selected for assay development based on 
specificity, selectivity and titer. Supernatant was collected from the hybridoma cells and immunoglobulins puri-
fied using HiTrap Protein G HP affinity columns according to manufacturer’s instructions (GE Healthcare Life 
Science, Buckinghamshire, UK).
PROM ELISA methodology. The PROM ELISA was as follows: 96-well streptavidin-coated ELISA plates 
(cat. no. 655995, Greiner Bio-One, Austria) were coated with 2.5 ng/mL biotinylated peptide dissolved in assay 
buffer (10 mM PBS-BTB, 8 g. NaCl, pH 7.4), 100 µL/well and incubated for 30 min at 20 °C in the dark with 
300 rpm shaking. Plates were washed five times in washing buffer (20 mM TRIS, 50 mM NaCl, pH 7.2). Subse-
quently, 20 µL of selection peptide or sample were added to appropriate wells, followed by 100 µL of 75 ng/mL 
horseradish peroxidase (HRP) conjugated monoclonal antibody. The plates were incubated for 20 h at 4 °C with 
shaking, and subsequently washed in washing buffer. Hundred µL per well of BM Chemiluminescence ELISA 
Substrate (POD) (cat. no. 11582950001, Roche, Switzerland) working solution was then added to the plate and 
incubated for 3  min at 20  °C with shaking. The plate was analyzed by a SpectraMax M5 reader (Molecular 
Table 2.  Patient demographics for the biological validation cohort. Categorical variables are expressed as 
number n [%] and were compared using Chi-square test; continuous variables as mean (SD) or median 
(IQR). SD standard deviation, BMI body mass index, SJC swollen joint count, TJC tender joint count, ASDAS 
the ankylosing spondylitis disease activity score, BASDAI bath ankylosing spondylitis disease activity index, 
BASMI bath ankylosing spondylitis meterology index, DAPSA disease activity in psoriatic arthritis score, DAS-
28 disease activity score-28 joints, LEI leeds enthesitis index, PASI psoriasis area and severity index, SPARCC 
spondyloarthritis research consortium of Canada, CRP C-reactive protein, VAS visual analogue scale, NSAID 
non-steroidal anti-inflammatory drug, DMARD disease modifying anti-rheumatic drugs. a ANOVA. b Mann–
Whitney U-test.
Variable
Controls
n = 55
Placebo
n = 55
PUFA
n = 56 p-value Completeness of data, %
Age, years 51.1 (14.6) 51.0 (11.8) 53.9 (11.7) 0.413a 100
Sex, male 23 [41.8] 24 [43.6] 23 [41.1] 0.961 100
PsA duration, years N/A 12.5 (6.0–18.0) 10.0 (5.5–19.0) 0.839b 99
BMI (kg/m2) N/A 26.9 (24.2–31.9) 28.3 (24.6–31.8) 0.528b 100
SJC N/A 0.0 (0.0–1.0) 0.0 (0.0–0.0) 0.310b 100
TJC N/A 2.0 (0.0–6.0) 1.0 (0.0–5.5) 0.892b 100
ASDAS N/A 2.4 (1.4–3.2) 2.0 (1.4–2.7) 0.146b 100
BASDAI N/A 35.0 (15.5–57.0) 28.5 (14.5–55.5) 0.365b 100
BASMI N/A 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.167b 100
DAPSA N/A 12.3 (7.4–17.3) 9.3 (3.9–17.9) 0.184b 100
DAS-28 N/A 2.6 (2.0–3.4) 2.5 (1.9–3.2) 0.246b 100
LEI N/A 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.983b 100
PASI N/A 1.2 (0.3–2.7) 0.6 (0.0–3.5) 0.717b 100
SPARCC N/A 2.0 (0.0–4.0) 1.0 (0.0–4.5) 0.744b 100
CRP (mg/L) N/A 4.2 (2.8–8.5) 2.9 (2.4–6.1) 0.193b 100
VAS global (mm) N/A 45.0 (21.0–62.5) 24.5 (11.5–56.0) 0.065b 100
VAS pain (mm) N/A 41.0 (20.5–57.8) 25.5 (11.5–48.0) 0.063b 100
Arthritis on X-ray N/A 28 [50.9] 24 [42.9] 0.398 100
NSAID use N/A 30 [54.5] 36 [64.3] 0.298 100
DMARD use N/A 37 [67.3] 47 [83.9] 0.042 100
Documented coronary heart disease N/A 3 [5.5] 4 [7.1] 0.716 100
Hypertension N/A 12 [21.8] 17 [30.9] 0.282 99
Hypercholesterolemia N/A 6 [10.9] 17 [30.4] 0.012 100
Total cholesterol, mmol/l N/A 4.8 (4.1–5.3) 4.9 (4.4–5.3) 0.394b 100
Systolic BP, mmHg N/A 134.5 (119.0–143.0) 139.0 (120.3–151.0) 0.281b 98
Diastolic BP, mmHg N/A 80.5 (74.0–89.0) 82.0 (73.0–87.8) 0.998b 98
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Devices, CA, USA) with settings: luminescence, Lm1 = 440 nm, Lm2 = 650 nm. A standard curve was generated 
by serial dilution of the selection peptide and plotted using a 4-parametric mathematical fit model. Standard 
concentrations were 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031, 0.016 and 0 ng/ml. Each plate included five kit con-
trols to monitor inter-assay variation. All samples were measured within the measurement range of the assay.
technical evaluation. To assess the linearity of the assay, four healthy human serum samples were used. 
The linearity was calculated as a percentage of recovery of the undiluted sample. The intra- and inter-assay 
variations were determined by ten independent runs of eight quality controls (QC) and two kit controls run in 
double determinations. Each run consisted of two replicas of double determinations of the samples. Lower limit 
of measurement range (LLMR) and upper limit of measurement range (ULMR) was calculated based on the 10 
individual standard curves from the intra- and inter-assay variation. The analyte stability was determined for 
three healthy human serum samples which were incubated at either 4 °C or 20 °C for 2, 4, 24 and 72 h respec-
tively. The stability of the samples was evaluated by calculating the percentage variation in proportion to the 
Figure 3.  Results from the biological relevance validation cohort. Serum levels of PROM was assessed in 
healthy controls (n = 55) and patients diagnosed with PsA (at baseline, n = 111). Data was analyzed using a 
Mann–Whitney U test. Data are presented as Tukey box-and-whisker plot. Significance threshold was set at 
p < 0.05, ***p = 0.0003.
Figure 4.  PROM levels in placebo and n-3 PUFA treated patients at baseline and 24 weeks. PROM levels were 
decreased in the Placebo group after 24 weeks. Significance threshold was set at p < 0.05 (Wilcoxon’s paired 
signed-rank test) and data is presented as Tukey box-and-whisker plot. *p = 0.049.
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Table 3.  Association with clinical assessment at baseline (all PsA patients pooled): Spearman’s correlations 
between baseline PROM biomarker concentration and other parameters for disease activity in the population 
with PsA. ASDAS the ankylosing spondylitis disease activity score, BASDAI bath ankylosing spondylitis 
disease activity index, BASMI bath ankylosing spondylitis meterology index, CRP C-reactive protein, DAPSA 
disease activity in psoriatic arthritis score, DAS-28 disease activity score-28 joints, HAQ health assessment 
questionnaire, LEI leeds enthesitis index, PASI psoriasis area and severity index, SJC swollen joint count, 
SPARCC spondyloarthritis research consortium of Canada, TJC tender joint count, VAS Visual analogue scale.
Spearman’s rho p
ASDAS 0.016 0.864
BASDAI 0.018 0.855
BASMI 0.043 0.651
CRP 0.000 0.999
DAPSA 0.072 0.451
DAS-28 0.090 0.346
HAQ − 0.049 0.611
LEI 0.156 0.101
PASI 0.046 0.633
SJC 0.064 0.501
SPARCC 0.110 0.249
TJC 0.121 0.207
VAS global − 0.012 0.904
VAS pain 0.001 0.994
Arthritis on x-ray 0.063 0.514
Table 4.  Association between PROM and sex, age, BMI, or disease duration. BMI body mass index.
Age Sex Years since diagnosis BMI
PROM at baseline
rho 0.103 − 0.013 − 0.027 − 0.167
P 0.2801 0.8962 0.7759 0.0791
Figure 5.  ROC curve analysis of the PROM biomarker for distinguishing subjects with PsA from healthy 
controls. AUC = 0.674, 95% CI 0.597–0.744, P < 0.001, Youden index J = 0.34, sensitivity 63.1, specificity 70.9, 
criterion > 0.22 (calculated with MedCalc DeLong et al., 1988 method).
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sample kept at − 20 °C (0 h sample). Stability of the analyte was also determined for three healthy human serum 
samples, exposed to four freeze and thaw cycles. The percentage of recovery was calculated using a reference 
sample that underwent only one freeze/thaw cycle. Stability and specificity of the generated monoclonal antibody 
to the standard peptide was also studied. The stability study included incubation of primary antibody at 4 °C, 
20 °C and 37 °C for 24 h, 72 h and 7 days. The specificity study included a nonsense peptide (KSVDQASSRK), 
an elongated peptide (FHDFSSDLENV), a truncated peptide (DFSSDLENV), a CHO-derived human PRELP 
protein (Gln21-Ile382, R&D Systems, MN, USA) and a nonsense coater (Biotin-KSVDQASSRK), used for deter-
mination of cross-reactivity. Accuracy was measured in three healthy human serum samples. The samples were 
spiked with known concentrations of a serum sample and spiking recovery was determined by calculating the 
percentage recovery of serum spiked in. Interference was measured in healthy human serum spiked with biotin 
(low = 3 ng/ml, high = 9 ng/ml), hemoglobin (low = 2.5 mg/mL, high = 5.0 mg/mL), or lipids (low = 1.5 mg/mL, 
high = 5.0 mg/mL). The interference was calculated as the percentage recovery using the analyte in non-spiked 
serum as reference. To define the standard concentration of PROM, the normal range was determined by analyz-
ing serum panel from 32 healthy donors (Supplementary Table S1) purchased from BioIVT (NY, USA).
Cleavage analysis. To evaluate the ability of MMP-1 (cat. no. G04MP01C, Giotto Biotech, Italy), MMP-2 
(cat. no. G04MP02C, Giotto Biotech, Italy), MMP-9 (cat. no. G04MP09C, Giotto Biotech, Italy), and MMP-13 
(cat. no. GAD00317, Giotto Biotech, Italy) to generate the PROM neo-epitope, 60 mg of human articular carti-
lage was incubated for 72 h at 37 °C with the aforementioned proteases. Six conditions were prepared as controls 
containing either MMP cleavage buffer, cartilage in cleavage buffer without MMPs, and individual MMPs in 
cleavage buffer without cartilage. The cleavage reactions were stopped using 1:1,000 dilution from 5 mM ethyl-
enediaminetetraacetic acid (EDTA). Cleavage products were stored at − 20 °C until analysis. All samples were 
prepared in duplicates.
Biological validation of PROM. The PsA cohort is described in detail in the study by Kristensen et al. 
(2016). Briefly, the study was conducted as a randomized, double-blind, placebo-controlled trial, where patients 
with PsA (defined by CASPAR) were supplemented with 3 g of n-3 PUFA or olive oil (control) daily for 24 weeks. 
Inclusion criteria were adults above 18 years of age with any disease activity, and exclusion criteria were: docu-
mented known cardiac arrhythmias, treatment with biological drugs, or treatment with oral corticosteroids. 
Compliance was assessed by counting capsules during the last visit and patients missing > 15% of capsules were 
excluded from analysis. Clinical assessment and blood samples (in a non-fasting state) were obtained at baseline 
and after 24 weeks of follow-up. Samples were processed immediately and stored at − 80 °C until  analysis33,34.
For comparison, a panel of age-, sex- and race- matched healthy controls was obtained from two commercial 
vendors: Discovery Life Science (AL, USA) and Lee Biosolutions (CA, USA). The healthy controls were collected 
in 2018 after informed consent and approval by the local Ethics Committee and with compliance with the Hel-
sinki Declaration of 1975, processed immediately after collection according to standard operating procedures 
and stored at − 80 °C until analysis.
All patients from the PsA cohort gave their written informed consent and the regional ethics committee of 
North Denmark region approved the study (reference number N20120076). The study was conducted in accord-
ance with the Declaration of Helsinki and registered at ClinicalTrials.gov (NCT01818804). Good clinical practice 
(GCP) inspectors monitored the study and the GCP ethical and scientific quality requirements were  followed33,34.
Statistical analysis. Characteristics of the cohort are presented as a number (frequency) and percent-
age for categorical variables and mean (standard deviation) or median (interquartile range) for normally and 
non-normally distributed continuous variables, respectively. Statistical differences for categorical variables 
were assessed using a Chi-squared test. For numerical variables, parametric tests (ANOVA, t-test) were used 
for normally distributed data, and nonparametric (Mann–Whitney U test, Kruskal–Wallis test and Spearman 
correlation) for non-normally distributed data. For all statistical analysis performed, a p-value below 0.05 was 
considered significant. Statistical analysis and graphs were performed using MedCalc Statistical Software version 
18.11.6 (MedCalc Software bvba, Ostend, Belgium) or GraphPad Prism version 8 (GraphPad Software, Inc., CA, 
USA). PROM levels below the LLMR were given the LLMR value.
ethical statement. The production of monoclonal antibodies performed in mice was approved by the 
Danish National Authority (The Animal Experiments Inspectorate) under approval number 2013-15-2934-
00956. All animals were treated according to the guidelines for animal welfare.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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